Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lansoprazole 15 mg for Frequent Heartburn
NCT00390390Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Lansoprazole 15 mg with Placebo (2 arms). Primary endpoint: Proportion of days with no heartburn during study treatment at 14 days. Started Jun 2006; status: completed.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00390390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390390.